NCT06370819View on ClinicalTrials.gov

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

November 27, 2024

Study Completion Date

November 27, 2024

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

NNC0519-0130

NNC0519-0130 will be administered subcutaneously.

Trial Locations (1)

10117

Charité Research Organisation GmbH, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY